Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir

(2017) Christian Wagner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine

(2017) Niloufar Marsousi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib

(2016) Neil J Parrott et al.   AAPS Journal

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

(2016) Shirish M. Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

(2016) Peter N. Morcos et al.   XENOBIOTICA

Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment

(2016) Katja Heinig et al.   Bioanalysis

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

(2014) Tatsushi Kodama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

(2014) Tatsushi Kodama et al.   CANCER LETTERS

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects

(2012) Richat Abbas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide

(2010) Anne Flint et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

(2010) Carlo L. Bello et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance

(2010) Trevor N. Johnson et al.   CLINICAL PHARMACOKINETICS

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

(2010) Ophelia Q.P. Yin et al.   CLINICAL THERAPEUTICS

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY